Companies › Eureka Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ECT204 GPC3-targeted autologous T-cell therapy (CAR-T cell therapy) | – | Phase 1 | Hepatocellular Carcinoma | Dec 2027 |
| ET140203 T Cells Autologous T cells expressing TCR targeting AFP | – | Phase 1 | Hepatoblastoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04634357 | ET140203 T Cells | Phase 1 | Hepatoblastoma | Oncology | Dec 2027 |
| NCT04864054 | ECT204 | Phase 1 | Hepatocellular Carcinoma | Oncology | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.